Caliway submits CBL-514 for FDA phase 2 weight management trial
December 26, 2025 | 11:44
The drug candidate aims to reduce fat and is being developed for use alongside existing GLP-1 receptor agonist therapies.
Caliway completed CBL-514 phase 2b study for subcutaneous fat reduction
October 24, 2024 | 00:42
Caliway Biopharmaceuticals completed CBL-514 Phase 2b study for non-surgical fat reduction on October 22 nd, 2024, with the topline results anticipated in Q1 2025.
Mobile Version